PFP-patients | Controls | p-value | |
---|---|---|---|
n | 55 | 23 | |
Years of age [mean ± SD] | 46.89 ± 19.3 | 43.1 ± 17.4 | 0.413 |
Females [n (%)] | 21 (38.2%) | 14 (60.9%) | 0.089 |
Leukocytes/µl blood [median (IQR)] | 7200 (3260) | 6980 (2370) | 0.042 |
% lymphocytes in blood [median (IQR)] | 26.0 (11.1) | 33.1 (5.4) | 0.002 |
Neutrophil/lymphocyte ratio [median (IQR)] | 2.42 (1.47) | 1.73 (0.48) | 0.004 |
Days between 1st and 2nd blood sampling, [mean ± SD] | 13.8 ± 2.1 (n = 36) | 14.0 ± 1.0 (n = 15) | 0.996 |
Clinical characteristics PFP | |||
Days since onset of symptoms [mean ± SD] | 2.6 ± 2.1 | n.a | |
House–Brackmann grading (1–6) [median (IQR)]# | 3.5 (1.5) | n.a | |
PFP side | |||
Left Right Bilateral | 32 (58.2%) 21 (38.2%) 2 (3.6%) | n.a n.a n.a | |
Lumbar puncture§ | (n = 47) | n.a | |
Normal cell counts (0–4 cells/µl) Borderline (5 cells/µl) Pleocytosis (> 5 cells/µl)* | 35 (74.5%) 4 (8.5%) 8 (17.0%) | n.a n.a n.a | |
PFP-treatment [n]$ | 52 | n.a | |
Steroids | 32 | ||
Anti-bacterialb | 1 | ||
Steroids/anti-virala | 2 | ||
Anti-virala/anti-bacterialb | 7 | ||
Steroids/anti-virala/anti-bacterialb | 8 | ||
Immunoglobulins | 2 |